1. Home
  2. Pfizer Inc Patent Portfolio Statistics

Pfizer Inc Patent Portfolio Statistics

Pfizer Inc

Pfizer Inc`s Profile

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Pfizer Inc look like?

Total Applications: 493
Granted Patents: 197
Grant Index 65.02 %
Abandoned/Rejected Applications: 106 (34.98%)
In-Process Applications: 190
Average Grant Time: 2.91 Years
Average Office Actions: 1.82

Which Technology Area Pfizer Inc is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1614 32
1624 Organic Chemistry 23
1612 Organic Compounds: Bio-affecting, Body Treating, Drug Delivery, Steroids, Herbicides, Pesticides, Cosmetics, and Drugs 20
1615 Organic Compounds: Bio-affecting, Body Treating, Drug Delivery, Steroids, Herbicides, Pesticides, Cosmetics, and Drugs 18
1617 Organic Compounds: Bio-affecting, Body Treating, Drug Delivery, Steroids, Herbicides, Pesticides, Cosmetics, and Drugs 16

How many patents are Pfizer Inc filing every year?

Year Total Applications
2022 0*
2021 0*
2020 0
2019 1
2018 2

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Pfizer Inc in USPTO?

Publication number: US20220023299A1

Abstract:
The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.

Publication date: 2022-01-27
Applicant: Pfizer Inc
Inventors: Esler Paul William


Publication number: US20220024893A1

Abstract:
This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.

Publication date: 2022-01-27
Applicant: Pfizer Inc
Inventors: Christopher Scott Seadeek


Publication number: US20220024894A1

Abstract:
This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.

Publication date: 2022-01-27
Applicant: Pfizer Inc
Inventors: Christian Eric Hansen


How are Pfizer Inc’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17498256 Combinations For Treatment Of Nash/Nafld And Related Diseases OPAP Central, Docket
17494923 Crystalline Forms Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate OPAP Central, Docket
17494938 Crystalline Forms Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate OPAP Central, Docket
17474561 Immunogenic Compositions And Uses Thereof Application Undergoing Preexam Processing OPAP Central, Docket
17463691 Immunogenic Compositions For Use In Pneumococcal Vaccines Docketed New Case – Ready for Examination OPAP Central, Docket